Skye Bioscience Inc (SKYE)

[AntonChigurh]

I don't think that is what Vinpat is saying. I think he means that Schneider has more concrete information in regards to items already made public by the CEO. I.e they have already stated (for some time) that they have been attempting to reach a licensing deal for NB1111. Schneider, through the process of the placement and doing their own DD, likely obtained information about the viability and structure of a deal. Having the resources and capital to do that is what affords that advantage.

Vinpat's 50x, or 5000%, might look a little silly but check my thread comparing the market caps and enterprise values of the industry. NMUS has a EV of 11m USD. CARA is 495m and GW is 2422m. NMUS is way behind in advancing their pipeline compared to those two, but the only thing stopping them was acquiring capital that didn't destroy shareholder value. Their IP is as impressive as anyone in the sector IMO. So Vinpat's 50x isn't that far-fetched given a long enough timeline...